Search results | co-marketing

Reports

Co-promotion and Co-marketing Agreements in Pharma, Biotech and Diagnostics

The Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics report provides comprehensive understanding and unprecedented access to the co-promotion and co-marketing partnering agreements entered into by the worlds leading healthcare companies. Revised and updated 10th edition, includes: Trends in co-promotion and co-marketing deals Co-promotion and co-marketing agreement structure Co-promotion and co-marketing more »

Global Joint Venture Partnerships in Pharma, Biotech and Diagnostics

The Global Joint Venture Partnerships in Pharma, Biotech and Diagnostics report provides comprehensive understanding and unprecedented access to the joint venture partnering agreements entered into by the worlds leading healthcare companies. This new 1st edition, includes: Trends in joint venture deals Joint venture agreement structure Joint venture contract documents Top joint venture deals by value more »

Insights

Co-promotion and Co-marketing: recent partnering industry trends

This article reflects on the latest industry trends in the co-marketing and co-promotion dealmaking in the biopharma sector. Two major forms of joint marketing are used to promote a product on the market, namely co-promotion and co-marketing. They are also referred to as joint marketing alliances.

Co-marketing

Two or more companies sell the same drug under different trademarks.

Current Agreements Deal Analysis Update : December 2014

This month we provide you with an overview of deal analysis in the life science sectors, covering partnering, M&A and financing in November 2014 and give you an exclusive opportunity to gain discounted annual subscription access to our database.

Pharma and biotech clinical stage partnering – recent trends 2009 to 2014

Partnering trends for the top pharma and biotech companies reviewed with over 2,000 deals analyzed – including summary biopharma deal financials

Current Agreements Deal Analysis Update : July 2014

This month we provide you with an overview of life science deal making activity, covering partnering, M&A and financing in June 2014.

Vaccine partnering

A vaccine is a biological preparation that improves immunity to a particular disease.

Joint marketing

A generic term to describe both co-promotion and co-marketing

Co-promotion

Two or more companies sell the same drug under the same trademark

Infectives vaccine partnering

A vaccine is a biological preparation that improves immunity to a particular disease

Top biopharma partnering deals of 2013

Deals, deals, deals everywhere and 2013 saw its fair share too; the pharmaceutical and biotech industry signed 3,122 between them which averaged out to 260 per month in a year that finished with a flurry of high valued deals.

Events

Sorry, your search returned no results.


Deals

Co-marketing and promotion agreement for complementary technologies simplifying ELISA development process

TGR BioSciences and Innova Biosciences have entered into an agreement to promote and co-market each other’s highly complementary technologies,

Co-marketing and distribution agreement for peanut allergy tests

Thermo Fisher Scientific Expands Access to Peanut Allergy Tests through Co-Marketing and Distribution Collaboration with Quest Diagnostics

MorphoSys and Celgene pharma deals for Oncology drug co-development and co-marketing in $818 million deal

MorphoSys, a big pharma, and Celgene, a big pharma and big biotech, announced pharma deals to jointly develop MOR202 globally and to co-promote MOR202 in Europe.

Merck KGaA / Ono: Co-development and co-marketing agreement for Stimuvax

Merck and Ono Pharmaceutical form collaborations to develop oral Multiple Sclerosis drug and cancer immunotherapy. 

Development, licensing and co-marketing agreement for GBR 500

Agreement to grant Sanofi a license for the development and commercialization of GBR 500, a novel monoclonal antibody for the treatment of Crohn’s Disease and other inflammatory conditions. Glenmark will receive an upfront payment of US$ 50 million, of which US$ 25 million will be paid upon closing of the transaction and US$ 25 million, more »

AZ, Daiichi ink co-marketing deal on Nexium

AstraZeneca and Daiichi Sankyo said they have agreed to co-promote and supply the heartburn treatment Nexium in Japan in a deal that includes a $100 million up-front payment to AstraZeneca.

Recordati signs agreement with Nycomed for co-marketing of Silodosin in Italy

License agreement with Nycomed S.p.A., the Italian subsidiary of the international pharmaceutical company, for the marketing and sales in Italy of silodosin, a new compound indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH). Nycomed will co-market the product together with Recordati in Italy.

Meda enters pharma deal for Elestrin in the US market

Meda has entered pharma deal into a promotion agreement with Mission Pharmacal, a company active in the women’s health area, for Meda’s topical estrogen replacement therapy product Elestrin.

Pharma news: GSK pays $90 million in Avandia settlement

GlaxoSmithKline, a top pharma company, topped the pharma news charts when imposed with allegations on illegal marketing of its diabetes drug, Avadia

Merck inks global oncology deal with Threshold

Threshold have landed a co-development and licensing deal to TH-302, a clinical candidate being developed for soft-tissue sarcoma and pancreatic cancer